|
End-of-day quote
Thailand S.E.
21/08/2026
|
5-day change | 1st Jan Change | ||
| 3.500 THB | -3.85% |
|
+0.57% | - |
| 08-21 | FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case | DJ |
| 08-20 | Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating | MT |
Evolution of the Average Target: Amgen Inc.
Evolution of the Target Price: Amgen Inc.
Changes in Analyst Recommendations: Amgen Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +5.34% | |||||
| +1.92% | |||||
| +5.64% | |||||
| -0.4% | |||||
| -2.48% | |||||
| +28.74% | |||||
| -10.43% | |||||
| +5.93% | |||||
| +9.74% | |||||
| Average | +4.89% | |||||
| Weighted average by Cap. | +4.45% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Piper Sandler | |
| Argus | |
| Morgan Stanley | |
| Mizuho Securities | |
| Cantor Fitzgerald | |
| Daiwa Securities | |
| Barclays | |
| HSBC | |
| Citigroup | |
| Rothschild & Co Redburn | |
| Canaccord Genuity | |
| Bernstein | |
| UBS | |
| JPMorgan Chase | |
| Wells Fargo Securities | |
| Leerink Partners | |
| TD Cowen | |
| Goldman Sachs | |
| BMO Capital | |
| Scotiabank | |
| Baird | |
| Oppenheimer | |
| BofA Securities | |
| RBC Capital Markets | |
| Truist Securities | |
| Guggenheim | |
| Deutsche Bank Securities | |
| DZ Bank | |
| DBS Bank | |
| Jefferies & Co. | |
| Redburn Atlantic | |
| William Blair & Co. | |
| Credit Suisse | |
| DA Davidson | |
| SVB Securities LLC | |
| Cowen | |
| Atlantic Equities | |
| SVB Leerink | |
| JPMORGAN | Cory Kasimov |
| RBC | Kennen Mackay |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN06 Stock
- Consensus Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
